Medically reviewed by a licensed healthcare professional. Last updated March 2026.
Key Takeaways
- Zepbound (tirzepatide) activates both GLP-1 and GIP receptors, which may produce faster and greater weight loss than GLP-1-only drugs.
- The SURMOUNT-1 trial showed average weight loss of 20.9% at the highest dose (15 mg) over 72 weeks.
- Many patients notice appetite changes within the first week, with meaningful weight loss often visible by weeks 4 to 6.
- Dose escalation takes a minimum of 20 weeks to reach the maximum 15 mg dose.
- Over half of patients in the SURMOUNT-1 trial lost 20% or more of their body weight, a result previously only seen with bariatric surgery.
What Makes Zepbound Different
Zepbound contains tirzepatide, a dual-action medication that targets both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism is what sets it apart from semaglutide-based medications like Ozempic and Wegovy, which only target GLP-1.
The GIP receptor activation adds additional metabolic effects, including enhanced insulin sensitivity and potentially greater effects on fat cell metabolism. In head-to-head comparisons, tirzepatide has consistently outperformed semaglutide for weight loss.
Zepbound Dose Escalation Schedule
Zepbound follows a step-wise dose increase:
| Period | Weekly Dose | Notes |
|---|---|---|
| Weeks 1-4 | 2.5 mg | Starting dose, adjustment period |
| Weeks 5-8 | 5.0 mg | First therapeutic dose |
| Weeks 9-12 | 7.5 mg | Optional increase |
| Weeks 13-16 | 10.0 mg | Higher therapeutic dose |
| Weeks 17-20 | 12.5 mg | Optional increase |
| Week 21+ | 15.0 mg | Maximum dose |
Your provider can hold you at any dose where you are seeing good results and tolerating the medication well. Not everyone needs to reach 15 mg. In clinical trials, significant weight loss occurred at 5 mg and 10 mg as well.
Week-by-Week: What Patients Typically Experience
Week 1 (2.5 mg)
Even at the starting dose, tirzepatide begins working on your appetite. Many patients report feeling less interested in food within the first 3 to 5 days. The dual mechanism means the appetite suppression signal can feel more pronounced than what people experience with semaglutide at the same point in treatment.
Side effects are typically mild: nausea, reduced appetite, and occasionally loose stools. Eating smaller meals and avoiding high-fat foods helps manage these.
Weeks 2-4 (2.5 mg)
By the end of month 1, the starting dose is fully established in your system. Weight loss of 3 to 6 pounds is common, slightly more than most patients see in the first month of semaglutide. The dual GIP/GLP-1 action may account for this faster initial response.
Weeks 5-8 (5.0 mg)
The 5.0 mg dose is the first fully therapeutic dose. Weight loss often accelerates here. In the SURMOUNT-1 trial, even the 5 mg dose group achieved average weight loss of 15.0% at 72 weeks, which is comparable to the highest dose of semaglutide (2.4 mg Wegovy) in the STEP trials.
Weeks 9-16 (7.5 to 10.0 mg)
Patients who continue dose escalation often see their most rapid weight loss during this period. The 10 mg dose in SURMOUNT-1 produced average weight loss of 19.5% at 72 weeks. Many patients find the appetite suppression at these doses to be very strong, and some need to consciously ensure they are eating enough protein and getting adequate nutrition.
Weeks 17+ (12.5 to 15.0 mg)
The highest doses push weight loss further. The 15 mg group in SURMOUNT-1 achieved 20.9% average body weight loss. At these doses, the medication's effect on appetite is powerful, and patients should work closely with their provider to ensure proper nutrition.
SURMOUNT Trial Data
The SURMOUNT-1 trial enrolled 2,539 adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one comorbidity, but without diabetes:
Weight Loss by Dose at 72 Weeks
| Dose | Average Weight Loss | Lost 5%+ | Lost 10%+ | Lost 20%+ |
|---|---|---|---|---|
| 5 mg | 15.0% | 85.1% | 69.5% | 33.9% |
| 10 mg | 19.5% | 88.9% | 78.9% | 49.1% |
| 15 mg | 20.9% | 90.9% | 83.5% | 56.7% |
| Placebo | 3.1% | 34.5% | 13.5% | 1.3% |
These results are significantly better than any semaglutide trial. For context, 56.7% of patients on the 15 mg dose lost at least 20% of their body weight. That level of weight loss was previously only achievable through bariatric surgery.
Zepbound vs. Semaglutide: Speed of Results
Some data suggests tirzepatide may produce noticeable results slightly faster than semaglutide. The SURMOUNT-3 trial, which started patients on an intensive lifestyle intervention before adding tirzepatide, showed that tirzepatide patients lost an additional 18.4% of body weight beyond what they had already achieved through lifestyle changes alone.
The dual receptor mechanism may contribute to this faster onset. GIP receptor activation enhances fat mobilization and energy expenditure in ways that GLP-1 alone does not. However, individual responses vary. Some patients respond better to semaglutide, and the best medication is the one that works for you with tolerable side effects.
Tips for Getting the Most Out of Zepbound
- Do not skip the dose escalation. It exists to prevent severe GI side effects. Jumping straight to high doses leads to intolerable nausea for most people.
- Prioritize protein. With reduced appetite, every bite counts. Aim for protein-first meals to prevent muscle loss.
- Stay hydrated. Tirzepatide can cause dehydration, especially combined with reduced food intake.
- Track your progress beyond the scale. Waist circumference, energy levels, and lab values (A1C, cholesterol, blood pressure) all improve with tirzepatide.
Ready to start your weight loss journey? Find a GLP-1 clinic near you and connect with a qualified provider today.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Individual results vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you are experiencing a medical emergency, call 911.